BACKGROUND: Previous studies indicate that negative symptoms reflect a separable domain of pathology from other symptoms of schizophrenia. However, it is currently unclear whether negative symptoms themselves are multi-faceted, and whether sub-groups of patients who display unique negative symptom profiles can be identified. METHODS: A data-driven approach was used to examine the heterogeneity of negative symptom presentations in two samples: Study 1 included 199 individuals with schizophrenia assessed with a standard measure of negative symptoms and Study 2 included 169 individuals meeting criteria for deficit schizophrenia (i.e., primary and enduring negative symptoms) assessed with a specialized measure of deficit symptoms. Cluster analysis was used to determine whether different groups of patients with distinct negative symptoms profiles could be identified. RESULTS: Across both studies, we found evidence for two distinctive negative symptom sub-groups: one group with predominantly Avolition-Apathy (AA) symptoms and another with a predominantly Diminished Expression (DE) profile. Follow-up discriminant function analyses confirmed the validity of these groups. AA and DE negative symptom sub-groups significantly differed on clinically relevant external validators, including measures of functional outcome, premorbid adjustment, clinical course, disorganized symptoms, social cognition, sex, and ethnicity. CONCLUSIONS: These results suggest that distinct subgroups of patients with elevated AA or DE can be identified within the broader diagnosis of schizophrenia and that these subgroups show clinically meaningful differences in presentation. Additionally, AA tends to be associated with poorer outcomes than DE, suggesting that it may be a more severe aspect of psychopathology.
BACKGROUND: Previous studies indicate that negative symptoms reflect a separable domain of pathology from other symptoms of schizophrenia. However, it is currently unclear whether negative symptoms themselves are multi-faceted, and whether sub-groups of patients who display unique negative symptom profiles can be identified. METHODS: A data-driven approach was used to examine the heterogeneity of negative symptom presentations in two samples: Study 1 included 199 individuals with schizophrenia assessed with a standard measure of negative symptoms and Study 2 included 169 individuals meeting criteria for deficit schizophrenia (i.e., primary and enduring negative symptoms) assessed with a specialized measure of deficit symptoms. Cluster analysis was used to determine whether different groups of patients with distinct negative symptoms profiles could be identified. RESULTS: Across both studies, we found evidence for two distinctive negative symptom sub-groups: one group with predominantly Avolition-Apathy (AA) symptoms and another with a predominantly Diminished Expression (DE) profile. Follow-up discriminant function analyses confirmed the validity of these groups. AA and DE negative symptom sub-groups significantly differed on clinically relevant external validators, including measures of functional outcome, premorbid adjustment, clinical course, disorganized symptoms, social cognition, sex, and ethnicity. CONCLUSIONS: These results suggest that distinct subgroups of patients with elevated AA or DE can be identified within the broader diagnosis of schizophrenia and that these subgroups show clinically meaningful differences in presentation. Additionally, AA tends to be associated with poorer outcomes than DE, suggesting that it may be a more severe aspect of psychopathology.
Authors: Gregory P Strauss; Rebecca C Wilbur; Kimberly R Warren; Sharon M August; James M Gold Journal: Psychiatry Res Date: 2011-02-05 Impact factor: 3.222
Authors: L Felice Reddy; Michael F Green; Shemra Rizzo; Catherine A Sugar; Jack J Blanchard; Raquel E Gur; Ann M Kring; William P Horan Journal: Schizophr Res Date: 2014-08-19 Impact factor: 4.939
Authors: Philip D Harvey; Elizabeth Deckler; Mackenzie T Jones; L Fredrik Jarskog; David L Penn; Amy E Pinkham Journal: J Psychiatr Res Date: 2019-05-10 Impact factor: 4.791
Authors: Thibaut Dondaine; Pierre Philippot; Jean-Marie Batail; Florence Le Jeune; Paul Sauleau; Sophie Drapier; Marc Vérin; Bruno Millet; Dominique Drapier; Gabriel Robert Journal: J Psychiatry Neurosci Date: 2019-01-01 Impact factor: 6.186
Authors: Karoline Schneider; Lars Michels; Matthias N Hartmann-Riemer; Achim Burrer; Philippe N Tobler; Philipp Stämpfli; Matthias Kirschner; Erich Seifritz; Stefan Kaiser Journal: J Psychiatry Neurosci Date: 2019-03-01 Impact factor: 6.186